Catalent Expert Invited To Speak On The Advantages Of Single Use Biomanufacturing




Catalent Expert Invited to Speak on the Advantages of Single Use Biomanufacturing for Facility Expansions at 2012 BPSA Summit

Somerset, NJ, July 19, 2012 — Michael Jenkins, Ph.D., General Manager of Catalent Pharma Solutions Middleton, WI biologics facility, will present “The Need for Speed: Why Single Use is Ideal for Cell Line Development and Bio-Manufacturing” at the 2012 Bio-Process Systems Alliance (BPSA) International Single Use Summit on July 23-25, in Washington, DC.

The presentation will discuss the decision making process, methodology, competitive advantages, strategic implementation and challenges related to adapting and transitioning to a single use manufacturing system versus a fixed stainless steel system.  In addition, the presentation will provide an update on the building process and highlight the theoretical business case versus the reality of implementation. 

Catalent helps customers achieve competitive advantage by producing stable, high-yielding mammalian cell lines, and by providing robust bio-manufacturing services with industry leading timelines.

Dr. Michael Jenkins has been with Catalent Pharma Solutions for more than nine years.  Before becoming General Manager of Catalent’s Middleton, WI facility, he held senior roles in Commercial Operations and as Vice President of Business Development.  Dr. Jenkins has previous industry experience in the development of mammalian cell culture and has also held technical roles at a plant transgenics company.  He was awarded his Ph.D. by the Department of Molecular and Cellular Biology at the University of Arizona, with a minor in Biochemistry and has a B.S. in Microbiology from the University of Illinois at Champaign Urbana.  Dr. Jenkins’ areas of interest include traditional and transgenic biologics manufacturing platforms, the evaluation and establishment of innovative technologies in the biotechnology marketplace and where these interests merge to reduce the cost of developing and manufacturing products.

For more information on the 2012 Bio-Process Systems Alliance (BPSA) International Single-Use Summit, please visit www.bpsalliance.org/summit .

To schedule an interview with Dr. Jenkins during or after the conference, please contact Patricia McGee at media@catalent.com .
 

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.™